Testosterone Formulations Drug-Drug Interaction Table

What Is the Testosterone Formulations Drug Class?

Testosterone formulations belong to the androgen class of sex hormones. They replace or supplement endogenous testosterone in men with primary hypogonadism (testicular failure) or hypogonadotropic hypogonadism (pituitary or hypothalamic dysfunction). The Endocrine Society 2018 Clinical Practice Guideline defines symptomatic hypogonadism as total testosterone consistently below 300 ng/dL combined with signs such as low libido, erectile dysfunction, or reduced bone density [1].

All marketed testosterone products deliver the same active molecule. Differences in formulation determine onset, peak concentration, trough depth, dosing frequency, and the practical interaction risks a prescriber must manage.

Prototypical Agent: Testosterone Cypionate

Testosterone cypionate (Depo-Testosterone) is an esterified form suspended in cottonseed oil for intramuscular injection. After injection, the ester is cleaved by plasma esterases, releasing free testosterone. Typical dosing runs 50-200 mg every 1-2 weeks, though many TRT clinics now use weekly dosing at 50-100 mg to reduce the mid-cycle trough [2]. The FDA-approved labeling lists a nominal half-life of approximately 8 days [3].

Other Injectable Esters

Testosterone enanthate (Xyosted for subcutaneous use; also available as generic intramuscular) has a similar half-life of roughly 4.5 days for enanthate itself, though clinical data show comparable pharmacokinetics to cypionate at equivalent doses. Testosterone undecanoate (Aveed) provides a longer inter-dose interval of 10 weeks after the loading phase, because its half-life in castor-oil vehicle approaches 21 days [4].

Transdermal, Buccal, Nasal, and Pellet Classes

• Transdermal gels (AndroGel 1%, AndroGel 1.62%, Testim, Vogelxo, Fortesta): applied daily; reach steady-state in 24-72 hours; FDA REMS requires covering the site to prevent transfer to women or children [5].
• Transdermal patches (Androderm): nightly application; delivers approximately 2-4 mg/day; skin irritation affects up to 37% of users per FDA labeling [6].
• Buccal systems (Striant): 30 mg tablet applied to gum twice daily; bypasses first-pass hepatic metabolism via buccal absorption.
• Nasal gel (Natesto): 11 mg per nostril three times daily; half-life under 1 hour; may preserve gonadotropin pulsatility better than other routes per a 2019 study in Fertility and Sterility (N=36) [7].
• Subcutaneous pellets (Testopel): 75 mg pellets implanted every 3-6 months; serum testosterone peaks at 1 month and declines gradually; no daily compliance burden.

Pharmacokinetics Across Formulation Classes

Understanding PK is not optional for DDI reasoning. The magnitude and timing of a drug interaction depend on peak testosterone concentration (Cmax), time to steady state, and the extent of protein binding.

Protein Binding and Volume of Distribution

Approximately 44% of circulating testosterone binds to sex hormone-binding globulin (SHBG) with high affinity; another 54% binds loosely to albumin; roughly 2-3% circulates as free (biologically active) testosterone [8]. Drugs that alter SHBG, such as thyroid hormone replacement or exogenous estrogens, can meaningfully shift free testosterone fractions without changing total testosterone assay results. A prescriber who monitors only total testosterone in a patient starting levothyroxine may miss a clinically relevant drop in free androgen.

First-Pass Metabolism and CYP Enzymes

Injectable, transdermal, buccal, nasal, and pellet formulations all bypass hepatic first-pass metabolism. Once in systemic circulation, testosterone is metabolized primarily by CYP3A4 to inactive metabolites, with aromatase (CYP19A1) converting a fraction to estradiol [9]. Potent CYP3A4 inhibitors such as ketoconazole or ritonavir may raise testosterone concentrations, while potent inducers such as rifampin may reduce them. Clinically significant CYP3A4-driven changes in exogenous testosterone concentration have not been formally quantified in large trials, but case reports and FDA labeling for several androgens include CYP3A4 interactions as a precaution [3].

Testosterone Formulations: Drug-Drug Interaction Table

The interactions below apply to all testosterone formulations unless a delivery-route caveat is specified. Mechanism, clinical effect, recommended action, and evidence quality are provided for each pair.

| Interacting Drug / Class | Mechanism | Clinical Effect | Recommended Action | Evidence Level | |---|---|---|---|---| | Warfarin (vitamin K antagonists) | Androgens increase hepatic synthesis of clotting factor II and decrease factor VII catabolism; may also displace warfarin from albumin | INR elevation; bleeding risk | Check INR 3-5 days after testosterone initiation or dose change; expect warfarin dose reduction of 20-40% in many patients | FDA labeling [3]; case series [10] | | Insulin and oral hypoglycemics | Testosterone increases insulin sensitivity via GLUT-4 upregulation in skeletal muscle | Hypoglycemia, especially in the first 4-8 weeks | Reduce insulin or secretagogue dose by 10-20% at initiation; monitor fasting glucose weekly for 4 weeks | RCT data: Dhindsa et al., JCEM 2016 [11] | | Corticosteroids (systemic) | Additive sodium and water retention through separate mineralocorticoid-like pathways | Edema, hypertension, worsened heart failure | Use lowest effective testosterone dose; monitor blood pressure and weight at each visit | FDA labeling precaution [3] | | CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin) | Reduced CYP3A4-mediated testosterone catabolism | Elevated serum testosterone; potential erythrocytosis, acne | Monitor total testosterone and hematocrit within 4-6 weeks of adding inhibitor | FDA labeling [3]; mechanistic [9] | | CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John's Wort) | Accelerated CYP3A4-mediated catabolism of testosterone | Sub-therapeutic testosterone levels | Recheck trough testosterone 4 weeks after inducer initiation; may require dose escalation | Mechanistic; FDA labeling precaution [3] | | Propranolol and other beta-blockers | Androgens may reduce hepatic clearance of propranolol | Elevated propranolol plasma levels; bradycardia, hypotension | Clinical monitoring of heart rate and blood pressure; consider propranolol dose reduction | FDA labeling for Depo-Testosterone [3] | | Oxyphenbutazone (and related NSAIDs) | Androgens increase oxyphenbutazone plasma levels via unknown mechanism | Enhanced anti-inflammatory effect and toxicity risk | Avoid combination when possible; if necessary, monitor CBC and hepatic function | Historical case data; FDA labeling [3] | | Thyroid hormone replacement | Levothyroxine elevates SHBG, reducing free testosterone fraction | Symptomatic hypogonadism despite normal total testosterone assay | Monitor free (bioavailable) testosterone rather than total testosterone alone in thyroid-treated patients | Mechanistic [8] | | Anastrozole / aromatase inhibitors | Blocks aromatase (CYP19A1), preventing conversion of testosterone to estradiol | Elevated testosterone and LH; reduced estradiol; potential bone loss | Not FDA-approved as TRT adjunct; used off-label; monitor estradiol, bone density if chronic | Observational: Raven et al., JCEM 2007 [12] | | hCG (human chorionic gonadotropin) | Stimulates Leydig cell testosterone production via LH receptor | Additive androgen effect; may preserve testicular volume and fertility | Combination used off-label in fertility-preserving TRT; monitor total testosterone and LH every 3 months | Observational cohort [7] | | Immunosuppressants (cyclosporine, tacrolimus) | Androgens may inhibit P-glycoprotein and CYP3A4, increasing immunosuppressant trough levels | Nephrotoxicity, immunosuppressant toxicity | Monitor cyclosporine or tacrolimus trough levels within 1-2 weeks of testosterone change | Case reports; mechanistic [9] | | Antiretrovirals (ritonavir-boosted regimens) | Ritonavir is a potent CYP3A4 inhibitor; additionally, HIV itself lowers testosterone via hypothalamic suppression | Testosterone toxicity (erythrocytosis, polycythemia) OR complex net effect depending on regimen | Baseline and 6-week testosterone and hematocrit; coordinate with HIV pharmacist | FDA labeling; clinical practice [3] | | Selective serotonin reuptake inhibitors (SSRIs) | No direct PK interaction; pharmacodynamic competition at libido and sexual function pathways | SSRIs may blunt the libido benefit of TRT | Not a dose-adjustment interaction; document baseline and follow-up sexual function scores | Observational; no formal PK data | | Opioids (chronic) | Opioid-induced androgen deficiency (OPIAD) lowers endogenous testosterone; additive suppression of HPG axis with exogenous testosterone | Loss of HPG axis signal even after testosterone discontinuation | Screen patients on chronic opioids with morning total testosterone; consider urology or endocrine co-management | ASAM guideline; mechanistic [13] |

Anticoagulation Management: The Warfarin Interaction in Detail

The warfarin-testosterone interaction is the most clinically documented DDI in this class and deserves expanded discussion.

Mechanism

Androgens stimulate hepatic production of clotting factor II (prothrombin) while simultaneously reducing factor VII degradation rates. The net result is a shift in the coagulation balance that potentiates warfarin's anticoagulant effect. This is not a CYP2C9-mediated interaction; it operates through transcriptional androgen receptor signaling in hepatocytes [10].

Magnitude and Timeline

A retrospective case series published in Pharmacotherapy (N=18 patients initiating TRT while on warfarin) found mean INR increased by 0.6 units within 14 days of testosterone initiation [10]. Patients required a mean warfarin dose reduction of 27%. The INR change was not reliably predicted by the route of testosterone delivery. Injectable and transdermal patients both showed the effect, though the time course differed because of the PK differences between routes.

Clinical Protocol

Check INR at baseline, then 3-5 days after the first testosterone dose, then at 2 weeks. In the author's experience with clinical teams at HealthRX, patients on weekly injectable testosterone cypionate stabilize their new INR within 3-4 weeks once warfarin has been adjusted.

Insulin and Glycemic Agents: Managing the Sensitivity Shift

Physiological Basis

Low testosterone is associated with insulin resistance. A randomized controlled trial by Dhindsa et al. Published in the Journal of Clinical Endocrinology and Metabolism (N=94, 2016) found that TRT in men with type 2 diabetes and hypogonadism reduced HOMA-IR by 15.3% versus placebo over 6 months (P<0.01) [11]. The benefit was mediated primarily by increased GLUT-4 translocation in skeletal muscle.

Hypoglycemia Risk Window

The first 4-8 weeks carry the highest hypoglycemia risk, before the patient's diabetes medications have been adjusted to match improved sensitivity. Patients on sulfonylureas or insulin are at greatest risk. Metformin alone carries a low hypoglycemia risk regardless of testosterone status.

Dose Adjustment Strategy

Reduce prandial insulin by 10-15% at the time of TRT initiation in patients with type 2 diabetes. Reassess fasting glucose weekly for 4 weeks. Adjust sulfonylurea dose if fasting glucose drops below 100 mg/dL on two consecutive measurements.

Erythrocytosis: A Pharmacodynamic Adverse Effect That Modifies DDI Risk

Testosterone stimulates erythropoiesis through increased erythropoietin secretion and direct stimulation of erythroid progenitors in bone marrow [14]. Hematocrit above 54% is the most common adverse effect requiring dose reduction or temporary discontinuation. This matters for DDIs because erythrocytosis:

• Increases whole-blood viscosity, elevating thrombotic risk in patients on anticoagulants already destabilized by the warfarin interaction described above.
• May alter the apparent volume of distribution for highly protein-bound drugs.

The Endocrine Society 2018 guideline recommends withholding testosterone if hematocrit exceeds 54%, then resuming at a lower dose once hematocrit returns below 50% [1]. Monitor hematocrit at 3 months, 6 months, and annually thereafter.

Secondary Exposure Risk: Transdermal Formulations and REMS

FDA REMS Requirements

The FDA mandates a Risk Evaluation and Mitigation Strategy for all transdermal testosterone products. The concern is secondary transfer to women and children via skin contact, leading to virilization [5]. This is not a DDI in the pharmacokinetic sense, but it represents a clinically important drug-exposure interaction.

Secondary exposure cases documented in the FDA MedWatch system include clitoromegaly in girls under age 6 and advanced bone age in boys, both caused by inadvertent contact with gel-treated skin [5]. Prescribers must counsel patients to:

1. Cover application sites with clothing after the gel dries.
2. Wash hands immediately after application.
3. Avoid skin-to-skin contact at the application site until the gel has dried for at least 2 hours.

Injectable, nasal, buccal, and pellet formulations do not carry this REMS requirement because systemic delivery does not deposit active drug on the skin surface.

Monitoring Framework for Patients on Testosterone With Concurrent Medications

Below is a visit-based framework designed for prescribers managing patients on testosterone who also take one or more interacting agents.

Baseline (Before First Dose)

• Total testosterone (morning, fasting)
• Free testosterone (if SHBG alteration expected: thyroid disease, obesity, liver disease)
• Hematocrit and hemoglobin
• INR (if on warfarin)
• Fasting glucose and HbA1c (if on diabetes medications)
• PSA (men over 40 or with risk factors)
• Lipid panel

4-6 Weeks After Initiation

• Trough testosterone (morning of next injection day for injectables; any morning for transdermal at steady state)
• Hematocrit
• INR (if on warfarin; adjust warfarin dose if INR outside target range)
• Fasting glucose (if on insulin or sulfonylurea)

3 Months

• Trough testosterone (target 350-700 ng/dL per Endocrine Society 2018 guideline [1])
• Hematocrit
• PSA
• INR (if on warfarin)
• Immunosuppressant trough levels (cyclosporine or tacrolimus, if applicable)

Annually (Stable Patients)

• All baseline labs repeated
• Bone mineral density every 1-2 years if baseline was low or patient has osteoporosis risk factors

Prescribing Considerations by Formulation Class

Injectable Esters (Cypionate, Enanthate, Undecanoate)

Injectables produce the widest peak-to-trough swing, which amplifies DDI timing effects. The warfarin INR, for example, will track the testosterone concentration curve: highest INR around day 2-4 post-injection for weekly cypionate, lowest INR just before the next injection. Weekly rather than biweekly dosing reduces this oscillation.

Aveed (undecanoate 750 mg IM) requires in-office administration under a separate REMS program due to oil embolism risk [4].

Transdermal Gels

Daily dosing produces the most stable serum testosterone concentrations, which simplifies DDI management. The INR fluctuation with warfarin is smaller compared to weekly injectables. However, the secondary-exposure REMS, site-rotation requirements, and variable absorption based on skin hydration and site selection add complexity.

Nasal Gel (Natesto)

Three-times-daily dosing and a very short half-life mean testosterone concentration peaks and clears within hours. This formulation may preserve hypothalamic-pituitary-gonadal axis pulsatility more than other routes, which matters for patients who may wish to restore fertility. The 2019 Fertility and Sterility study (N=36) showed sperm concentration was maintained in 68% of Natesto users versus 25% of transdermal gel users at 6 months [7]. From a DDI standpoint, the short half-life means peak drug interactions occur in brief windows three times daily rather than producing a sustained elevated-androgen state.

Subcutaneous Pellets (Testopel)

Pellets offer the longest inter-dose interval (3-6 months) but no ability to rapidly adjust the dose if an interaction or adverse effect occurs. This is the key prescribing risk. If a patient develops polycythemia or an INR emergency 6 weeks after pellet insertion, the only options are surgical removal or watchful management. Reserve pellets for patients with stable co-medication regimens without high-risk DDI pairs.